COMP <GO>
PCVX vs JNJ // 10Y YIELD & FRED MACRO BETA
Vaxcyte Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: PCVX 3
— JNJ 9
▲ 10Y YIELD & FRED MACRO BETA LEADER: JNJ
LAST: $62.03 (-0.93%) • MKT CAP: $9.85B
macro-sensitivity
1.07
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
macro-sensitivity
1.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCVX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCVX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.60% | 25.50% | -53.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.79% | 2.97% | -9.76 | JNJ | /fcf-yield <GO> |
| Operating Margin | -33.50% | 34.70% | -68.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.50% | -28.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 19.80% | 6.00% | +13.80 | PCVX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 18.11 | 5.59 | +12.52 | PCVX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | PCVX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.8 | 60.4 | -11.54 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.07 | 1.08 | -0.01 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 23.0x | 0.00 | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.85B | $662.49B | -$652.64B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCVX REV | JNJ REV | PCVX GROSS % | JNJ GROSS % | PCVX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | -$669.3M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$475.1M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | -$296.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCVX // BETA 1.07
JNJ // BETA 1.08